Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) COO Sells 12,905 Shares of Stock

by · The Cerbat Gem

Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Free Report) COO Jeremy Chadwick sold 12,905 shares of the firm’s stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $79.36, for a total transaction of $1,024,140.80. Following the transaction, the chief operating officer directly owned 48,297 shares in the company, valued at $3,832,849.92. This trade represents a 21.09% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Kymera Therapeutics Stock Up 1.2%

Shares of Kymera Therapeutics stock traded up $0.93 on Wednesday, reaching $81.70. The stock had a trading volume of 330,315 shares, compared to its average volume of 667,424. The company has a 50 day moving average price of $83.24 and a 200 day moving average price of $78.99. Kymera Therapeutics, Inc. has a 1 year low of $28.33 and a 1 year high of $103.00. The stock has a market capitalization of $6.72 billion, a P/E ratio of -22.89 and a beta of 2.06.

Kymera Therapeutics (NASDAQ:KYMR – Get Free Report) last issued its quarterly earnings data on Thursday, April 30th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.18. Kymera Therapeutics had a negative net margin of 611.94% and a negative return on equity of 24.71%. The firm had revenue of $34.37 million for the quarter, compared to the consensus estimate of $8.27 million. During the same quarter in the previous year, the firm earned ($0.82) EPS. The company’s quarterly revenue was up 55.5% compared to the same quarter last year. On average, analysts forecast that Kymera Therapeutics, Inc. will post -3.34 earnings per share for the current fiscal year.

Institutional Trading of Kymera Therapeutics

Several large investors have recently bought and sold shares of KYMR. Smartleaf Asset Management LLC grew its position in Kymera Therapeutics by 382.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after purchasing an additional 424 shares during the last quarter. Larson Financial Group LLC lifted its stake in Kymera Therapeutics by 81.5% during the 3rd quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock valued at $44,000 after acquiring an additional 349 shares during the period. Osaic Holdings Inc. lifted its stake in Kymera Therapeutics by 18,050.0% during the 2nd quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after acquiring an additional 1,083 shares during the period. Bessemer Group Inc. lifted its stake in Kymera Therapeutics by 652.0% during the 3rd quarter. Bessemer Group Inc. now owns 940 shares of the company’s stock valued at $53,000 after acquiring an additional 815 shares during the period. Finally, Caitong International Asset Management Co. Ltd acquired a new stake in Kymera Therapeutics during the 4th quarter valued at approximately $63,000.

Analyst Ratings Changes

KYMR has been the topic of a number of analyst reports. Stephens lifted their price objective on shares of Kymera Therapeutics from $95.00 to $100.00 and gave the stock an “overweight” rating in a research report on Monday, March 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Kymera Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen raised shares of Kymera Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 2nd. Barclays boosted their target price on shares of Kymera Therapeutics to $133.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 27th. Finally, Jefferies Financial Group began coverage on shares of Kymera Therapeutics in a research report on Monday, March 16th. They set a “buy” rating and a $110.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Kymera Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $118.10.

Read Our Latest Analysis on Kymera Therapeutics

Kymera Therapeutics Company Profile

(Get Free Report)

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.

Recommended Stories